Browse by category

A clinical research team at UT Health San Antonio, the academic health centre of The  University of Texas at San Antonio, has been awarded a five-year, nearly $4 million grant from the National Institutes of Health’s National Institute of Diabetes and Digestive and Kidney Diseases for a first-of-its-kind study to explore the many roles glucagon plays in human metabolism. Glucagon historically was seen only as insulin’s counterbalance, raising blood sugar during periods when i

For decades, scientists have known that what harms the body often harms the brain. Conditions such as obesity, high blood pressure and insulin resistance strain the body's vascular and metabolic systems. Over time, that stress can speed up cognitive decline and increase the risk of Alzheimer's disease. Now, researchers at Arizona State University and their collaborators report that these effects may begin far earlier than expected. This graphic shows how obesity in young adul

A study conducted at Harvard University has identified a group of metabolites that travel from the intestine to the liver and then to the heart, where they are pumped throughout the body. These metabolites play an important role in controlling metabolic pathways in the liver and insulin sensitivity. This discovery may contribute to future treatments for obesity and type 2 diabetes. Diagram summarising the experiments, which analyzed metabolites present in the peripheral blood

Soybean oil, the most widely consumed cooking oil in the US and a staple of processed foods, contributes to obesity, at least in mice, through a mechanism scientists are now beginning to understand. Soybean oil consumption has increased alongside obesity in the US (Credit: Sonia Deol/UCR) In an experiment conducted at University of California - Riverside, most mice on a high-fat diet rich in soybean oil gained significant weight. However, a group of genetically engineered mic

Novo Nordisk announced the submission of a sNDA to the FDA for a higher dose of semaglutide injection 7.2 mg, to be used along with a reduced calorie diet and increased physical activity for chronic weight management in adults with obesity. Under the CNPV expedited program, review is expected within 1–2 months following the FDA's acceptance of the filing. The sNDA includes results from STEP UP, a 72-week phase 3, randomised, double-blind, placebo-controlled and active-control

Welcome to our regular round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have looked far and wide to give you an overview of papers including side-to-side compression anastomosis, surgery and mortality and kidney transplants, Indian surgeons’ perspectives on obesity, and obesity-associated vs overall deaths, and more (please note, log-in maybe required to access the full paper). Creation of Side-to-Side Compression An

The magnitude and composition of post- metabolic-bariatric surgery (MBS) weight loss were not associated with incident major adverse cardiovascular events (MACE) and mortality in the total population, according to an international team of researchers. They also reported that a high total weight loss and a disproportional composition of weight loss with a relatively high fat-free mass loss, were associated with a greater risk of adverse outcomes in middle-aged and older patien

The initial results of a study assessing the combination of the Allurion Program with low-dose tirzepatide therapy to optimize muscle mass and GLP-1 adherence, has reported that after 12 months, the average total body weight loss was 23%, and lean body mass as a percentage of total body weight increased by 14% from 62% to 70%. “These results provide additional data that a combination approach with the Allurion Smart Capsule and GLP-1 medications has several advantages,” said

Innovent Biologics’ supplementary application for the 9 mg dosage of mazdutide, an innovative glucagon (GCG)/ glucagon-like peptide-1 (GLP-1) dual receptor agonist, for the long-term weight management in adults with moderate to severe obesity has been accepted for review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). This application of mazdutide 9 mg aims to address a pressing unmet clinical need in China by offering a hig

The oral GLP-1, orforglipron, can help adults with obesity and type 2 diabetes lose more weight and improve their blood sugar levels compared to a placebo, according to findings from the ATTAIN-2 trial led by researchers from the University of Texas Health Science Center at Houston, TX. Orforglipron (Image credit: Jovan.gec) "The opportunity for an oral GLP-1 medication with highly effective weight loss that is simpler to take may provide increased access and opportunities fo